Click here to get full coverage on Interesting DNLI Call Options For April 17th - Nasdaq

Interesting DNLI Call Options For April 17th  Nasdaq

Interesting DNLI Call Options For April 17th - Nasdaq

Click here to get full coverage on Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions - Yahoo Finance

Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions  Yahoo Finance

Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions - Yahoo Finance

Click here to get full coverage on Is Denali Therapeutics (DNLI) the most promising mid-cap healthcare stock under $50? - MSN

Is Denali Therapeutics (DNLI) the most promising mid-cap healthcare stock under $50?  MSN

Is Denali Therapeutics (DNLI) the most promising mid-cap healthcare stock under $50? - MSN

Click here to get full coverage on Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review - simplywall.st

Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review  simplywall.st

Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review - simplywall.st

Click here to get full coverage on $DNLI stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

$DNLI stock is down 11% today. Here's what we see in our data.  Quiver Quantitative

$DNLI stock is down 11% today. Here's what we see in our data. - Quiver Quantitative

Click here to get full coverage on Hunter syndrome drug nears FDA decision as new brain therapies move ahead - Stock Titan

Hunter syndrome drug nears FDA decision as new brain therapies move ahead  Stock Titan

Hunter syndrome drug nears FDA decision as new brain therapies move ahead - Stock Titan

Click here to get full coverage on DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - Zacks Investment Research

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug  Zacks Investment Research

DNLI Posts Narrower-Than-Expected Q3 Loss, Advances MPS IIIA Drug - Zacks Investment Research

Click here to get full coverage on The Bull Case For Denali Therapeutics (DNLI) Could Change Following NEJM Tividenofusp Data Publication And FDA Review - Yahoo Finance

The Bull Case For Denali Therapeutics (DNLI) Could Change Following NEJM Tividenofusp Data Publication And FDA Review  Yahoo Finance

The Bull Case For Denali Therapeutics (DNLI) Could Change Following NEJM Tividenofusp Data Publication And FDA Review - Yahoo Finance

Click here to get full coverage on Interesting DNLI Put And Call Options For September 18th - Nasdaq

Interesting DNLI Put And Call Options For September 18th  Nasdaq

Interesting DNLI Put And Call Options For September 18th - Nasdaq

Click here to get full coverage on Insider Sale: President and CEO of $DNLI Sells 35,198 Shares - Quiver Quantitative

Insider Sale: President and CEO of $DNLI Sells 35,198 Shares  Quiver Quantitative

Insider Sale: President and CEO of $DNLI Sells 35,198 Shares - Quiver Quantitative

Click here to get full coverage on Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review - Yahoo Finance

Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review  Yahoo Finance

Assessing Denali Therapeutics (DNLI) Valuation After Positive Hunter Syndrome Trial Data And FDA Priority Review - Yahoo Finance

Click here to get full coverage on Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound - Yahoo Finance

Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound  Yahoo Finance

Denali Therapeutics (DNLI): Rethinking Valuation After a 33% One-Month Share Price Rebound - Yahoo Finance

Click here to get full coverage on Denali Therapeutics (DNLI): Evaluating Valuation Disconnect Despite Lack of Major News - Yahoo Finance

Denali Therapeutics (DNLI): Evaluating Valuation Disconnect Despite Lack of Major News  Yahoo Finance

Denali Therapeutics (DNLI): Evaluating Valuation Disconnect Despite Lack of Major News - Yahoo Finance

Click here to get full coverage on Denali Therapeutics (DNLI): Exploring Valuation After Recent Share Price Rebound - Yahoo Finance

Denali Therapeutics (DNLI): Exploring Valuation After Recent Share Price Rebound  Yahoo Finance

Denali Therapeutics (DNLI): Exploring Valuation After Recent Share Price Rebound - Yahoo Finance

Click here to get full coverage on DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 - Yahoo Finance

DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26  Yahoo Finance

DNLI Tops on Q2 Earnings, Expects Decree on Hunter Syndrome Drug in '26 - Yahoo Finance

Click here to get full coverage on H.C. Wainwright Reiterates “Buy” Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results - Yahoo Finance

H.C. Wainwright Reiterates “Buy” Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results  Yahoo Finance

H.C. Wainwright Reiterates “Buy” Rating on Denali Therapeutics (DNLI) With $32 PT Following Q3 Results - Yahoo Finance

Click here to get full coverage on FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months - Yahoo Finance

FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months  Yahoo Finance

FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months - Yahoo Finance

Click here to get full coverage on Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? - Yahoo Finance

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report?  Yahoo Finance

Why Is Denali Therapeutics (DNLI) Up 16.2% Since Last Earnings Report? - Yahoo Finance

Click here to get full coverage on Denali: Regulatory Delay Is A Strategic Opportunity (NASDAQ:DNLI) - Seeking Alpha

Denali: Regulatory Delay Is A Strategic Opportunity (NASDAQ:DNLI)  Seeking Alpha

Denali: Regulatory Delay Is A Strategic Opportunity (NASDAQ:DNLI) - Seeking Alpha

Click here to get full coverage on Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring An 83% Upside Potential - DirectorsTalk Interviews

Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring An 83% Upside Potential  DirectorsTalk Interviews

Denali Therapeutics Inc. (DNLI) Stock Analysis: Exploring An 83% Upside Potential - DirectorsTalk Interviews

Click here to get full coverage on DNLI: Imminent approval and strong clinical progress drive growth for transferrin receptor-enabled therapies - TradingView — Track All Markets

DNLI: Imminent approval and strong clinical progress drive growth for transferrin receptor-enabled therapies  TradingView — Track All Markets

DNLI: Imminent approval and strong clinical progress drive growth for transferrin receptor-enabled therapies - TradingView — Track All Markets

Click here to get full coverage on How Tividenofusp’s Brain-Penetrant MPS II Data And FDA Priority Review At Denali (DNLI) Has Changed Its Investment Story - simplywall.st

How Tividenofusp’s Brain-Penetrant MPS II Data And FDA Priority Review At Denali (DNLI) Has Changed Its Investment Story  simplywall.st

How Tividenofusp’s Brain-Penetrant MPS II Data And FDA Priority Review At Denali (DNLI) Has Changed Its Investment Story - simplywall.st

Click here to get full coverage on Denali Therapeutics (NASDAQ: DNLI) plans $200M stock, pre-funded warrant sale with $30M option - Stock Titan

Denali Therapeutics (NASDAQ: DNLI) plans $200M stock, pre-funded warrant sale with $30M option  Stock Titan

Denali Therapeutics (NASDAQ: DNLI) plans $200M stock, pre-funded warrant sale with $30M option - Stock Titan

Click here to get full coverage on BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - Yahoo Finance

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target  Yahoo Finance

BTIG Reiterates a Buy Rating on Denali Therapeutics (DNLI) With a $32 Price Target - Yahoo Finance

Click here to get full coverage on Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50 - Stock Titan

Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50  Stock Titan

Denali Therapeutics (NASDAQ: DNLI) prices $200M equity deal at $17.50 - Stock Titan

Click here to get full coverage on Retail Trends: What is the Moat Score of DNLI - Earnings Recap Report & Verified Technical Trade Signals - baoquankhu1.vn

Retail Trends: What is the Moat Score of DNLI - Earnings Recap Report & Verified Technical Trade Signals  baoquankhu1.vn

Retail Trends: What is the Moat Score of DNLI - Earnings Recap Report & Verified Technical Trade Signals - baoquankhu1.vn

Click here to get full coverage on Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) - Yahoo Finance

Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI)  Yahoo Finance

Denali’s Royalty Deal to Fund Hunter Syndrome Drug Could Be A Game Changer For Denali Therapeutics (DNLI) - Yahoo Finance

Click here to get full coverage on Have Denali Therapeutics Insiders Been Selling Stock? - simplywall.st

Have Denali Therapeutics Insiders Been Selling Stock?  simplywall.st

Have Denali Therapeutics Insiders Been Selling Stock? - simplywall.st

Click here to get full coverage on Why (DNLI) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Why (DNLI) Price Action Is Critical for Tactical Trading  Stock Traders Daily

Why (DNLI) Price Action Is Critical for Tactical Trading - Stock Traders Daily

Click here to get full coverage on DNLI January 2026 Options Begin Trading - Nasdaq

DNLI January 2026 Options Begin Trading  Nasdaq

DNLI January 2026 Options Begin Trading - Nasdaq

Click here to get full coverage on PDUFA moved to Apr 5, 2026 — Denali's Tividenofusp Alfa BLA review extended by FDA (Major Amendment) - Stock Titan

PDUFA moved to Apr 5, 2026 — Denali's Tividenofusp Alfa BLA review extended by FDA (Major Amendment)  Stock Titan

PDUFA moved to Apr 5, 2026 — Denali's Tividenofusp Alfa BLA review extended by FDA (Major Amendment) - Stock Titan

Click here to get full coverage on Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI) - Seeking Alpha

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI)  Seeking Alpha

Denali: Maintaining Strong Buy Based On DNL126 Expansion As MPS IIIA Treatment (DNLI) - Seeking Alpha

Click here to get full coverage on Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants  GlobeNewswire

Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire

Click here to get full coverage on Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy - Yahoo Finance

Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy  Yahoo Finance

Denali Therapeutics Inc. (DNLI) Secures FDA Priority Review for First-Ever Brain-Penetrant Hunter Syndrome Therapy - Yahoo Finance

Click here to get full coverage on Should You Reconsider Denali Therapeutics After This Year’s Collaboration and FDA News? - simplywall.st

Should You Reconsider Denali Therapeutics After This Year’s Collaboration and FDA News?  simplywall.st

Should You Reconsider Denali Therapeutics After This Year’s Collaboration and FDA News? - simplywall.st

Click here to get full coverage on Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages  MarketBeat

Denali Therapeutics Inc. (NASDAQ:DNLI) Given Consensus Rating of "Buy" by Brokerages - MarketBeat

Click here to get full coverage on Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI) - Seeking Alpha

Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI)  Seeking Alpha

Denali Therapeutics: Navigating Through Recent Setbacks (NASDAQ:DNLI) - Seeking Alpha

Click here to get full coverage on DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review - Yahoo Finance

DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review  Yahoo Finance

DNLI's BLA for Hunter Syndrome Drug Gets FDA's Priority Review - Yahoo Finance

Click here to get full coverage on Have Denali Therapeutics Insiders Been Selling Stock? - Sahm

Have Denali Therapeutics Insiders Been Selling Stock?  Sahm

Have Denali Therapeutics Insiders Been Selling Stock? - Sahm

Click here to get full coverage on Denali Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative

Denali Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants  Quiver Quantitative

Denali Therapeutics Inc. Announces $200 Million Public Offering of Common Stock and Pre-Funded Warrants - Quiver Quantitative

Click here to get full coverage on Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth  Yahoo Finance

Companies Like Denali Therapeutics (NASDAQ:DNLI) Are In A Position To Invest In Growth - Yahoo Finance

Click here to get full coverage on BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - 富途资讯

BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29  富途资讯

BofA Securities Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Maintains Target Price $29 - 富途资讯

Click here to get full coverage on Why You Shouldn't Bet Against Denali (DNLI) Stock - Yahoo Finance

Why You Shouldn't Bet Against Denali (DNLI) Stock  Yahoo Finance

Why You Shouldn't Bet Against Denali (DNLI) Stock - Yahoo Finance

Click here to get full coverage on Denali Therapeutics unveils portfolio goals for 2026, stock up - MSN

Denali Therapeutics unveils portfolio goals for 2026, stock up  MSN

Denali Therapeutics unveils portfolio goals for 2026, stock up - MSN

Click here to get full coverage on We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate - simplywall.st

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate  simplywall.st

We're Not Very Worried About Denali Therapeutics' (NASDAQ:DNLI) Cash Burn Rate - simplywall.st

Click here to get full coverage on Denali Enters Into a $275M Funding Deal With Royalty Pharma - December 5, 2025 - Zacks Investment Research

Denali Enters Into a $275M Funding Deal With Royalty Pharma - December 5, 2025  Zacks Investment Research

Denali Enters Into a $275M Funding Deal With Royalty Pharma - December 5, 2025 - Zacks Investment Research

Click here to get full coverage on New Analyst Forecast: $DNLI Given $31 Price Target - Quiver Quantitative

New Analyst Forecast: $DNLI Given $31 Price Target  Quiver Quantitative

New Analyst Forecast: $DNLI Given $31 Price Target - Quiver Quantitative

Click here to get full coverage on DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Yahoo Finance

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up  Yahoo Finance

DNLI Begins Rolling BLA Submission for Hunter Syndrome Drug, Stock Up - Yahoo Finance

Click here to get full coverage on UBS Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $25 - 富途资讯

UBS Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $25  富途资讯

UBS Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Cuts Target Price to $25 - 富途资讯

Click here to get full coverage on Denali Therapeutics Inc Announces Key Milestones and Priorities for 2026 - TradingView — Track All Markets

Denali Therapeutics Inc Announces Key Milestones and Priorities for 2026  TradingView — Track All Markets

Denali Therapeutics Inc Announces Key Milestones and Priorities for 2026 - TradingView — Track All Markets

Click here to get full coverage on Denali Therapeutics prices stock offering at $17.50 per share - MSN

Denali Therapeutics prices stock offering at $17.50 per share  MSN

Denali Therapeutics prices stock offering at $17.50 per share - MSN

Click here to get full coverage on FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months - Finviz

FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months  Finviz

FDA Extends Review of DNLI's Hunter Syndrome Drug by Three Months - Finviz

Click here to get full coverage on Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up - Yahoo Finance

Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up  Yahoo Finance

Denali Therapeutics Unveils Portfolio Goals for 2026, Stock Up - Yahoo Finance

Click here to get full coverage on Denali Therapeutics stock falls after announcing $200 million public offering - Investing.com

Denali Therapeutics stock falls after announcing $200 million public offering  Investing.com

Denali Therapeutics stock falls after announcing $200 million public offering - Investing.com

Click here to get full coverage on DNLI Stock Price, News & Analysis - Stock Titan

DNLI Stock Price, News & Analysis  Stock Titan

DNLI Stock Price, News & Analysis - Stock Titan

Click here to get full coverage on Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $31 - 富途资讯

Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $31  富途资讯

Wedbush Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Raises Target Price to $31 - 富途资讯

Click here to get full coverage on Technical Reactions to DNLI Trends in Macro Strategies - Stock Traders Daily

Technical Reactions to DNLI Trends in Macro Strategies  Stock Traders Daily

Technical Reactions to DNLI Trends in Macro Strategies - Stock Traders Daily

Click here to get full coverage on Denali Therapeutics Earns RS Rating Upgrade - Investor's Business Daily

Denali Therapeutics Earns RS Rating Upgrade  Investor's Business Daily

Denali Therapeutics Earns RS Rating Upgrade - Investor's Business Daily

Click here to get full coverage on Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress - Investing.com Nigeria

Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress  Investing.com Nigeria

Denali Therapeutics stock maintains Buy rating at Goldman Sachs on pipeline progress - Investing.com Nigeria

Click here to get full coverage on Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants  GlobeNewswire

Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants - GlobeNewswire

Click here to get full coverage on Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Yahoo Finance

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025?  Yahoo Finance

Is Denali Therapeutics Inc. (DNLI) Among Jeff Bezos’ Investments in 2025? - Yahoo Finance

Click here to get full coverage on Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewswire

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights  GlobeNewswire

Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights - GlobeNewswire

Click here to get full coverage on Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch - Investing.com

Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch  Investing.com

Denali Therapeutics stock maintains Buy rating at Stifel ahead of 2026 launch - Investing.com

Click here to get full coverage on Denali Therapeutics Announces Extension of FDA Review Timeline for Tividenofusp Alfa in Hunter Syndrome Treatment - Quiver Quantitative

Denali Therapeutics Announces Extension of FDA Review Timeline for Tividenofusp Alfa in Hunter Syndrome Treatment  Quiver Quantitative

Denali Therapeutics Announces Extension of FDA Review Timeline for Tividenofusp Alfa in Hunter Syndrome Treatment - Quiver Quantitative

Click here to get full coverage on First Brain-Penetrating Hunter Syndrome Treatment in 20 Years Gets FDA Priority Review - Stock Titan

First Brain-Penetrating Hunter Syndrome Treatment in 20 Years Gets FDA Priority Review  Stock Titan

First Brain-Penetrating Hunter Syndrome Treatment in 20 Years Gets FDA Priority Review - Stock Titan

Click here to get full coverage on Denali Therapeutics announces board and leadership changes - Investing.com

Denali Therapeutics announces board and leadership changes  Investing.com

Denali Therapeutics announces board and leadership changes - Investing.com

Click here to get full coverage on How DNLI stock reacts to job market data - July 2025 Chart Watch & Safe Entry Momentum Stock Tips - ulpravda.ru

How DNLI stock reacts to job market data - July 2025 Chart Watch & Safe Entry Momentum Stock Tips  ulpravda.ru

DNLI

Price Chart

Key Statistics

Technicals

About DNLI

Latest News

Interesting DNLI Call Options For April 17th - Nasdaq

Denali Therapeutics (DNLI): Assessing Valuation After $200 Million Secondary Offering and FDA Voucher Discussions - Yahoo Finance

Is Denali Therapeutics (DNLI) the most promising mid-cap healthcare stock under $50? - MSN

Advanced Charts

Top Gainers

Top Losers